We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+3.92%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$57M
AUM Growth
-$35K
Cap. Flow
+$3.12M
Cap. Flow %
5.48%
Top 10 Hldgs %
93.01%
Holding
19
New
1
Increased
3
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
ABEO icon
Abeona Therapeutics
ABEO
+$6.26M
2
AVXL icon
Anavex Life Sciences
AVXL
+$2.58M
3
AIXC
AIxCrypto Holdings Inc
AIXC
+$1.21M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$193K

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$4.32M
2
TOVX icon
Theriva Biologics
TOVX
+$1.99M
3
ADXS
Advaxis Inc
ADXS
+$450K
4
CSBR icon
Champions Oncology
CSBR
+$184K
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$111K

Sector Composition

Rank Sector Weight
1 Healthcare 94.69%
2 Technology 4.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
1
Corbus Pharmaceuticals
CRBP
$170M
$21.7M 38.01%
85,464
– –
ABEO icon
2
Abeona Therapeutics
ABEO
$345M
$11.4M 20.08%
94,391
+40,000
+74% +$6.26M
NTBL
3
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$4.17M 7.32%
24,589
– –
AVXL icon
4
Anavex Life Sciences
AVXL
$222M
$2.87M 5.03%
+724,205
New +$2.58M
AIXC
5
AIxCrypto Holdings Inc
AIXC
$16.6M
$2.58M 4.53%
8
+4
+100% +$1.21M
ARCT icon
6
Arcturus Therapeutics
ARCT
$157M
$2.53M 4.44%
172,214
+12,883
+8% +$193K
AMPE
7
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$2.49M 4.37%
9,128
– –
VNRX icon
8
VolitionRx Ltd
VNRX
$12M
$2.09M 3.67%
23,077
– –
ADXS
9
DELISTED
Advaxis Inc
ADXS
$1.61M 2.83%
15,000
-3,333
-18% -$450K
TOVX icon
10
Theriva Biologics
TOVX
$10.2M
$1.55M 2.72%
233
-194
-45% -$1.99M
KERX
11
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.17M 2.06%
200,000
– –
LUMO
12
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$962K 1.69%
10,393
-989
-9% -$111K
ALDX icon
13
Aldeyra Therapeutics
ALDX
$91.7M
$727K 1.28%
135,800
– –
ADXSW
14
DELISTED
Advaxis Inc Warrants
ADXSW
$446K 0.78%
112,500
– –
NBSE
15
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$306K 0.54%
510
-3
-0.6% -$3.17K
ENLV icon
16
Enlivex Ltd
ENLV
$70.7M
$214K 0.38%
343
-75
-18% -$63.5K
LSTA icon
17
Lisata Therapeutics
LSTA
$15.2M
$157K 0.28%
3,705
-14
-0.4% -$804
CSBR icon
18
Champions Oncology
CSBR
$85.1M
– –
-111,111
Closed -$184K
CEMP
19
DELISTED
Cempra, Inc.
CEMP
– –
-180,800
Closed -$4.32M

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Knoll Capital Management held 19 positions worth $57M, down 0.06% from $57M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Knoll Capital Management deployed $3.12M of net new capital in Q4 2016, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Anavex Life Sciences: 724,205 shares worth $2.87M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Theriva Biologics, an estimated $1.99M trimmed.

  • Knoll Capital Management's largest Q4 2016 buy was Anavex Life Sciences: 724,205 shares worth $2.87M.
  • Knoll Capital Management added most to Abeona Therapeutics in Q4 2016, an estimated $6.26M increase.
  • Knoll Capital Management's biggest Q4 2016 reduction was Theriva Biologics, cutting an estimated $1.99M.
  • Knoll Capital Management fully exited Cempra, Inc. in Q4 2016, selling an estimated $4.32M.
  • Knoll Capital Management's ten largest holdings make up 93% of its $57M portfolio in Q4 2016.
  • Knoll Capital Management opened 1 new position and closed 2 in Q4 2016.
  • Knoll Capital Management's portfolio value fell 0.06% quarter-over-quarter to $57M.

Based on Knoll Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.